Celltrion Signs 210 Billion KRW Supply Contract for COVID-19 Rapid Test Kits in the US
SampleNut, a COVID-19 antigen diagnostic kit jointly developed by Celltrion and diagnostic device specialist BBB
View original image[Asia Economy Reporter Choi Dae-yeol] Celltrion announced on the 2nd that its U.S. subsidiary, CelltrionUSA, has signed a contract to supply COVID-19 diagnostic kits worth 210 billion KRW to a local distributor.
The diagnostic kit being supplied this time is called "Sampinut" and uses a rapid antigen detection method. It recently received emergency use authorization from the U.S. Food and Drug Administration (FDA). The supply target is Prime Healthcare Distributors, a specialized wholesale distributor of diagnostic kits and personal protective equipment located in New York, USA, with an exclusive local distribution rights contract until June next year.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- After Topping 8,000 Instead of Hitting 10,000... KOSPI Plunges—When Will It Rebound?
- "They Said It's Impossible to Get—Already Selling for Triple the Price: Crowds Worldwide Line Up for $600 Luxury Watch"
- Song Unseok: "6.3 Local Elections to Check Lee Administration's Unilateral Rule... Only a Strong Public Warning Can Stop Reckless Governance"
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
The COVID-19 diagnostic kit supplied this time can provide results within 10 minutes using portable specialized equipment. It was jointly developed with BBB, a domestic diagnostic device specialist company. The company explained that it shows a sensitivity of over 94% compared to the existing RT-PCR method.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
